Pfizer emergency Supreme Court request
Pfizer asks the Supreme Court May 29 to vacate the Federal Circuit U.S. Court of Appeals' ruling that its Norvasc patent is invalid until the court takes action on its concurrently filed petition for certiorari. The Federal Circuit denied Pfizer's request for an en banc review of its decision (1"The Pink Sheet" May 28, 2007, p. 23). Pfizer argues that the Federal Circuit "used a flawed analytical framework" in applying the Supreme Court's recent ruling in KSR v. Teleflex as to what constitutes an obvious patent...
You may also be interested in...
The pharmaceutical and biotech industries were dealt a blow when the Federal Circuit U.S. Court of Appeals decided not to reconsider its ruling that Pfizer's Norvasc (amlodipine besylate) patent is obvious
A Medicines for Europe report on policies affecting the off-patent industry across 22 European countries aims to demonstrate the urgent need for pricing and reimbursement and procurement reforms.
After a difficult spell for the Belgian biotech, positive interim data from two key studies looking at testicular toxicity concerns over filgotinib suggest a pathway for potential future US approval of the Gilead-partnered JAK inhibitor for IBD.